Journal of General Internal Medicine

, Volume 23, Issue 10, pp 1673–1678

The Impact of the Medicare Part D Prescription Benefit on Generic Drug Use

  • James X. Zhang
  • Wesley Yin
  • Shawn X. Sun
  • G. Caleb Alexander
Original Article

DOI: 10.1007/s11606-008-0742-6

Cite this article as:
Zhang, J.X., Yin, W., Sun, S.X. et al. J GEN INTERN MED (2008) 23: 1673. doi:10.1007/s11606-008-0742-6



Little information exists regarding the impact of Medicare Part D on generic drug use.


To examine changes in the use of generic prescriptions attributable to Part D among a sample of Medicare beneficiaries.

Design, participants, and measurements

Difference-in-difference analysis of pharmacy claims of Part D enrollees and non-enrollees aged 67–79 years from 2005 to 2006. The final sample represented approximately 2.4 million unique subjects. Analyses were conducted separately for major therapeutic classes, limited to subjects filling at least one prescription within the class during 2005 and 2006, and adjusted for subject characteristics, prescription characteristics, socio-demographic characteristics measured through zipcode-linked Census data, baseline differences between Part D and non-Part D enrollees, and secular trends in generic use.


Generic drugs accounted for 58% of total prescriptions. Among the entire group of beneficiaries, there was a trend of increased generic drug use in 13 out of 15 drug classes examined. However, after adjusting for potential confounders, the growth rate of generic drug use was lower among Part D enrollees than among non-enrollees; enrollees were slightly less likely to fill prescriptions for generic drugs vs. brand-name drugs in 2006 compared to 2005 (odds ratio 0.95, 95% confidence interval 0.94–0.95).


Despite secular trends of increased utilization of generic drugs among both Part D enrollees and non-enrollees, the net impact of Part D among these beneficiaries was a modest decrease in the use of generic drugs. This finding, which is consistent with economic theory but contrary to several recent reports, highlights the complexity of assessing the impact of Part D on overall consumer welfare.


medicare Part Dprescription coveragepharmacoepidemiologygeneric drugs

Copyright information

© Society of General Internal Medicine 2008

Authors and Affiliations

  • James X. Zhang
    • 1
  • Wesley Yin
    • 2
    • 3
    • 4
  • Shawn X. Sun
    • 5
  • G. Caleb Alexander
    • 2
    • 6
    • 7
    • 8
  1. 1.Department of Pharmacy, School of PharmacyVirginia Commonwealth UniversityRichmondUSA
  2. 2.Center for Health and Social SciencesUniversity of ChicagoChicagoUSA
  3. 3.Harvard University, Robert Wood Johnson Scholars Program in Health PolicyCambridgeUSA
  4. 4.University of Chicago, Harris School of Public PolicyChicagoUSA
  5. 5.Health Outcomes Department, Walgreens Health ServicesDeerfieldUSA
  6. 6.Section of General Internal Medicine, Department of MedicineUniversity of ChicagoChicagoUSA
  7. 7.MacLean Center for Clinical Medical EthicsUniversity of ChicagoChicagoUSA
  8. 8.Department of Pharmacy PracticeUniversity of Illinois at Chicago School of PharmacyChicagoUSA